After menopause your cholesterol moved and nobody explained why. The number on the page is real and so is the biology behind it. Estrogen carries a large share of the cardiovascular protection a woman's body relied on for decades and when ovarian production stops, the lipid picture shifts within a few years. LDL cholesterol and ApoB rise, triglycerides creep upward and the blood vessels lose a layer of the flexibility they had. A decade of stable labs then produces a result that reads like a lifestyle failure, when what actually happened is a physiological transition nobody sat down and explained. Here is what the transition does, which markers catch it early and what a plan that reads the whole system looks like.
- Estrogen withdrawal after menopause raises LDL and ApoB and shifts triglycerides within a few years.
- Arterial stiffness increases with the transition, which is measurable and real.
- The standard panel often reads normal while ApoB and insulin resistance quietly move.
- The Biomarker Audit reads lipids, ApoB, Lp(a), hs-CRP, HbA1c, fasting insulin and thyroid every 90 days.
- Hormone therapy is a clinical decision made with a clinician, never promised by any article.
What actually changes after menopause
The cardiovascular story of menopause is the story of estrogen withdrawal and it has measurable parts. Total and LDL cholesterol commonly rise through the years of the transition. ApoB rises with them and because ApoB counts the particles that enter the artery wall, the atherogenic burden often moves even when the composite cholesterol numbers look mild. Triglycerides trend upward, particularly with the insulin resistance that also becomes more common in this window and body fat redistributes toward the abdomen in ways the scale alone understates. Blood vessels lose elastic recoil and blood pressure often drifts upward alongside. None of this is a character failure. It is the physiology of a system losing a hormone it had relied on since puberty.
The reason it catches women off guard is the cadence of routine care. A panel once a year, read against ranges built for a different decade of life, tells a woman her numbers are mildly elevated and hands her a pamphlet. What the annual cadence cannot show is the slope. A quarterly read of the same markers shows whether the shift is settling, stable or still climbing and the slope is what determines how urgently the system needs a plan.
The numbers moved because the hormones moved. The panel that reads both is the only one that explains the trajectory instead of just reporting it.
The markers that matter in this window
Three groups of markers carry the post-menopausal cardiovascular picture and a complete panel reads all three. The lipoprotein burden group is ApoB and the full lipid panel, with Lp(a) measured at least once because it is inherited and fixed and it decides how aggressively everything else should be managed. The metabolic group is HbA1c and fasting insulin, because insulin resistance accelerates in the menopausal transition and drives both the lipid shift and the central weight change. The inflammation group is hs-CRP, which rises with the visceral adiposity and the arterial stiffness of the transition. The Biomarker Audit reads all of these, plus thyroid function, because the thyroid symptoms of midlife overlap with the menopausal ones and the two systems interact. It repeats every 90 days through the Beluga Health lab network.
What the panel changes is the target. A statin conversation that started on a total cholesterol number becomes a conversation about a particle count that can be tracked quarter to quarter. An unexplained weight shift becomes a measured insulin resistance with a protocol. The fatigue and the joint aches that got attributed to aging get their thyroid panel. Each marker either earns its place in the plan or clears something out of it and the quarterly cadence keeps the plan honest as the transition completes.
The hormone therapy question, answered honestly
We will not use this article to promise hormone therapy, because it is a genuine clinical decision with real history behind it. The old labeling from the early 2000s cast hormone therapy as broadly risky and decades of subsequent work have refined that picture considerably, timing and type and route all matter and for many women in the early transition the risk-benefit calculus is different from the one the old studies implied. The honest summary is that the question is individual, the evidence is nuanced and the decision belongs to a clinician who reads your full history and your full panel rather than to a pamphlet or a headline.
What we can promise is the structure in which that decision gets made well. The panel is drawn before any prescription. Hormone therapy, where a clinician judges it appropriate, is prescribed by licensed physicians of Beluga Health, P.A., an independent Florida professional corporation licensed to practice in all 50 states, working under GoodLife Health's clinical protocols. Any prescription is billed by the pharmacy you choose at that pharmacy's own price and we take nothing on it. The fee never rises with the dose and there is no molecule upcharge, so the decision about hormones is never a decision about revenue.


What the membership includes and costs
The Cardiometabolic Optimization Membership is one flat $299 a month covering the clinical relationship, four quarterly Biomarker Audits, asynchronous messaging with the care team and video visits and your own health platform, where every result, visit and medication builds into one Health Story with Cassandra to help you understand your numbers. It starts with a $598 hold on your card covering the first two months, charged only once a clinician accepts you into care and released if the clinician cannot accept you. Once accepted, the first two months are charged and nonrefundable and from month three the membership is month to month. Additional labs beyond the quarterly cadence, when a clinician orders them for a specific question, are billed at pass-through cost with no markup.
Who this is not for
If you have a cardiologist and a gynecologist who coordinate, draw the full panel and explain the transition to you, that is excellent care and this membership adds nothing essential to it. If you want hormone therapy promised on arrival rather than evaluated, we are the wrong door, because testing first is the model and the decision belongs to the clinician. We are built for the woman whose lipid numbers moved after menopause, whose questions about why outran the visit and who wants one clinical home reading the whole system every quarter.
FAQ
Why did my cholesterol rise after menopause?
Estrogen withdrawal is the main driver. LDL cholesterol and ApoB commonly rise through the transition, triglycerides trend upward and arterial stiffness increases. It is physiology, not a lifestyle failure and the markers that track it can be measured and managed.
What is ApoB and why does it matter here?
Apolipoprotein B counts the atherogenic particles directly, one molecule per particle. It often rises in the transition even when the composite cholesterol numbers look mild, which is why the annual panel misses it.
Should Lp(a) be measured in this window?
At least once in a lifetime, yes. Lp(a) is inherited and fixed and an elevated result changes how aggressively every other cardiovascular risk factor should be managed.
Is the weight change in menopause metabolic?
Partly, yes. Insulin resistance accelerates in the transition and drives central fat redistribution along with the lipid shift, which is why fasting insulin and HbA1c belong in the panel.
Is hormone therapy safe after menopause?
The evidence is nuanced and the decision is individual. Timing, type and route all matter and the old one-line risk claim has been substantially refined. The decision belongs to a clinician reading your full history and panel and it is never promised by an article.
What does the membership cost?
One flat $299 a month with a $598 hold covering the first two months, charged only once a clinician accepts you and released if the clinician cannot accept you. Four audits a year sit inside the fee and medication is billed separately by your pharmacy at its own price.
How often are labs drawn?
Every 90 days. The markers of the transition move over months, so a quarterly cadence shows the slope of the change rather than one snapshot a year.
One last thing
Nobody explained the shift because the appointment was eight minutes and the panel was partial. The explanation exists, the markers that measure it exist and the plan that manages it quarterly exists. Ask for ApoB and fasting insulin by name at your next visit and if the answer is no, you now know exactly what was never checked.
Related guides
- ApoB and LDL: which number predicts heart attack risk
- Menopause and weight gain: how hormones drive the change
- What labs to run before starting hormone therapy
- Hormone optimization at GoodLife Health
References
- El Khoudary SR et al. Menopause transition and cardiovascular disease risk, Circulation, 2020. pubmed.ncbi.nlm.nih.gov/33104670
- American Heart Association, menopause and heart disease risk. heart.org
- American College of Cardiology, cholesterol management guidance. acc.org